Dernières nouvelles pour Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Kymera Therapeutics Inc

Throughout the last three months, 16 analysts have evaluated Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $161.69, a high estimate of $198.00, and a low estimate of $127.00. Highlighting a 0.37% decrease, the current average has fallen from the previous average price target of $162.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1731931217_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Hyatt Hotels among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$153.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$198.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Michael Bellisario</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$158.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$144.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Carlo Santarelli</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$127.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$164.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Meredith Jensen</td>
<td>HSBC</td>
<td>Announces</td>
<td>Hold</td>
<td>$156.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Shaun Kelley</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Duane Pfennigwerth</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$155.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$169.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$151.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Richard Clarke</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$178.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hyatt Hotels. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hyatt Hotels compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Hyatt Hotels's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Hyatt Hotels's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/H/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hyatt Hotels analyst ratings.</a>
<h2>Unveiling the Story Behind Hyatt Hotels</h2>
Hyatt is an operator of owned (4% of total rooms) and managed and franchised (96%) properties across around 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 54% Americas, 22% rest of world, and 23% Asia-Pacific.
<h3>Unraveling the Financial Story of Hyatt Hotels</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Hyatt Hotels's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.43% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Hyatt Hotels's net margin excels beyond industry benchmarks, reaching 28.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hyatt Hotels's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 12.48%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.83%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.93, Hyatt Hotels adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Hyatt Hotels In The Eyes Of 16 Experts

On Monday, Eco Wave Power Global AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAVE#NASDAQ">WAVE</a>) announced it had received the final Nationwide Permit (NWP) from the U.S. Army Corps of Engineers for its groundbreaking wave energy project at AltaSea&#8217;s premises at the Port of Los Angeles.
According to the company, this marks a significant step forward in developing Eco Wave Power&#8217;s wave energy project, which will likely become the first onshore wave energy installation in the United States.
The permit, issued under NWP 52 for Water-Based Renewable Energy Generation Pilot Projects, authorizes Eco Wave Power to install eight wave energy floaters on the piles of an existing concrete wharf structure on the east side of Municipal Pier One.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/42015847/meta-wants-to-fight-back-order-allowing-states-and-schools-to-sue-over-social-media-addiction" rel="noreferrer noopener">Meta Wants To Fight Back Order Allowing States and Schools To Sue Over Social Media Addiction</a>
The system will also include an energy conversion unit comprised of two 20-foot shipping containers, which will be placed on the wharf deck and connected to the floaters.
With the conversion unit already shipped and located on-site, Eco Wave Power plans to complete installation by the end of the first quarter of 2025.
In addition to securing the final permit, this achievement marks the completion of two key milestones under Eco Wave Power&#8217;s agreement with Shell International Exploration and Production Inc, which will likely boost the company&#8217;s revenues in fourth-quarter of 2024
The agreement between the parties was announced in April 2024. According to the agreement, Eco Wave Power and Shell will collaborate to develop a wave energy pilot in the Port of Los Angeles.
Now, with the permit in place, the parties will enter the project&#8217;s execution phase as per the agreement&#8217;s terms.
Inna Braverman, CEO and Founder of Eco Wave Power emphasized that this project is a pivotal technological advance and an essential move toward accelerating the shift to renewable energy.
The U.S. Department of Energy&#8217;s National Renewable Energy Laboratory estimates that wave energy can generate over 1,400 terawatt-hours annually to power approximately 130 million homes.
With this project, Eco Wave Power is advancing the commercialization of wave energy as a reliable and clean renewable power source, further strengthening its position as a leader in the industry.
In November, Eco Wave Power named Ran Atias Vice President of Engineering at the company&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41714843/eco-wave-power-strengthens-management-appoints-new-vice-president-of-engineering-to-accelerate-exe" rel="noreferrer noopener">Tel Aviv headquarters</a>.
Atias has extensive experience managing complex projects across industries like automotive, defense, and robotics and aims to enhance engineering efficiency and speed up project timelines, the company said.
The company is advancing three new projects in the U.S., Taiwan, and Portugal, expecting Atias to play a strategic role in scaling its technology and accelerating growth.
Price Action: WAVE stock closed lower by 1.80% at $6.56 at Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42011906/exxon-mobil-set-to-cut-400-texas-jobs-after-pioneer-deal" target="_blank" rel="noreferrer noopener">Exxon Mobil To Cut 400 Texas Jobs In Stages Through 2026</a></li>
</ul>
Photo via Company

Government

News

Regulations

Market-Moving Exclusives

Exclusives

WAVE

EXCLUSIVE: Eco Wave Power Gets Green Light From US Army For First Onshore Wave Energy Project In LA

Across the recent three months, 13 analysts have shared their insights on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.85, along with a high estimate of $106.00 and a low estimate of $87.00. This current average reflects an increase of 4.28% from the previous average price target of $91.92. 
<img src="https://www.benzinga.com/files/images/story/2024/1731931210_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Medtronic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$93.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Perform</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Medtronic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Medtronic analyst ratings.</a>
<h2>Get to Know Medtronic Better</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>A Deep Dive into Medtronic's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Medtronic showcased positive performance, achieving a revenue growth rate of 2.77% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Medtronic's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.12%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Medtronic's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.16%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.58.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Medtronic's Future

EXCLUSIVE: Eco Wave Power Tells Benzinga Co. Receives Final Permit From U.S. Army Corps Of Engineers For U.S. First Wave Energy Project At Port Of Los Angeles

The JV is expected to deploy approximately $500 million, including debt, to acquire newly constructed homes. The JV will be initially capitalized with a total equity commitment of $200 million, of which $50 million will be committed by Invitation Homes, with potential to upsize equity commitments through follow-on investment tranches in the future. The Company will provide various management services to the JV, for which the Company will earn management fees in addition to the opportunity to earn a promoted interest subject to certain performance thresholds. Invitation Homes also has certain rights to potentially acquire the JV's homes in the future.

INVH

Invitation Homes Enters $200M Joint Venture, Sets Sights On $500M Investment In New Home Communities

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Biotricity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCY#NASDAQ">BTCY</a>) with a Neutral.

Reiteration

BTCY

HC Wainwright & Co. Reiterates Neutral on Biotricity

MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support the energy transformation, today announced that it intends to offer, subject to market conditions and other factors, $700 million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). MARA also expects to grant to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $105 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed.
The notes will be unsecured, senior obligations of MARA and will bear interest payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2025. The notes will mature on March 1, 2030, unless earlier repurchased, redeemed or converted in accordance with their terms. Subject to certain conditions, on or after March 5, 2028, MARA may redeem for cash all or any portion of the notes. If MARA redeems fewer than all the outstanding notes, at least $75 million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date. Holders of the notes will have the right to require MARA to repurchase for cash all or any portion of their notes on December 1, 2027. The notes will be convertible into cash, shares of MARA's common stock, or a combination of cash and shares of MARA's common stock, at MARA's election. Prior to December 1, 2029, the notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The interest rate, initial conversion rate, and other terms of the notes will be determined at the time of pricing of the offering. MARA expects that the reference price used to calculate the initial conversion price for the notes will be the U.S. composite volume weighted average price of MARA's common stock from 2:00 p.m. through 4:00 p.m. Eastern Daylight Time on the date of pricing.
MARA expects to use up to $200 million of the net proceeds from the sale of the notes to repurchase a portion of its existing convertible notes due 2026 (the "existing 2026 convertible notes") in privately negotiated transactions with the remainder of the net proceeds to be used to acquire additional bitcoin and for general corporate purposes, which may include working capital, strategic acquisitions, expansion of existing assets, and repayment of additional debt and other outstanding obligations.

Offerings

MARA

MARA Holdings Announces $700M Convertible Note Offering to Boost Bitcoin Holdings and Debt Repurchase

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Sphere 3D (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANY#NASDAQ">ANY</a>) with a Buy and maintains $3 price target.

Price Target

HC Wainwright & Co. Reiterates Buy on Sphere 3D, Maintains $3 Price Target

HC Wainwright &amp; Co. analyst Kevin Dede maintains My Size (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYSZ#NASDAQ">MYSZ</a>) with a Buy and lowers the price target from $5 to $3.

MYSZ

HC Wainwright & Co. Maintains Buy on My Size, Lowers Price Target to $3

Liberty Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>, "Liberty" or the "Company"))) today commented on the announcement by President-elect Donald J. Trump regarding his nomination of Chris Wright, Liberty's Founder, Chairman of the Board, Director and Chief Executive Officer, for the position of U.S. Secretary of Energy. The appointment of Mr. Wright as Secretary of Energy is subject to confirmation by the U.S. Senate, and Mr. Wright will continue in his current positions with the Company until confirmation occurs.
Effective upon and subject to this confirmation and in accordance with the Company's succession plan, the Board of Directors intends to appoint William Kimble as non-executive Chairman of the Board and Ron Gusek as Chief Executive Officer.
"I am deeply honored by this nomination and opportunity to serve our country and continue the mission of bringing affordable, reliable energy to the citizens of the United States and beyond," commented Mr. Wright.
Mr. Wright continued, "Succession planning has been a priority of the Board. Having worked closely with both Bill and Ron, Liberty will be in the safest of hands upon my departure. Ron has been a close partner to me for over two decades and possesses all the criteria to ensure Liberty continues leading the industry in technology innovation and service quality while delivering growth for our valued shareholders."
Mr. Kimble has been a member of the Board of Directors since the Company's initial public offering in January 2018 and has served as Lead Director since October 2018. Mr. Gusek joined Liberty in 2014 and has served as President of the Company since November 2016.

Management

LBRT

Liberty Energy CEO Chris Wright Nominated for US Energy Secretary, Eyes William Kimble As New chair And Ron Gusek As CEO

Oscar Health, Inc. ("Oscar") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>), a leading healthcare technology company, today announced that the Anahata Foundation ("Anahata"), a charitable foundation established by Mark T. Bertolini, Oscar's Chief Executive Officer, purchased 933,333 shares on the open market the week of November 11, 2024. Oscar was not a party to any of these transactions.
Bertolini said: "I believe in the future of Oscar. I am convinced Oscar is the company with the talent, products, and technology to change healthcare. The future is bright. My continued investment in Oscar reiterates my confidence in our growth, in the team, and in our opportunity to make the individual market the chosen solutions for all Americans."

OSCR

Oscar Health CEO's Foundation Purchases Nearly 1 Million Shares, Signaling Confidence in Company's Future

Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome.
As previously disclosed, on November 11,2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response that has been reported with systemic exposure to high doses of AAV. Hyperinflammatory syndromes are associated with aberrant cytokine release and include hemophagocytic lymphohistiocytosis (HLH) and multisystem inflammatory syndrome. The participant is in critical condition, and the case is continuing to evolve.
"We are deeply saddened for the family. While no words could possibly provide comfort to her family, we ask the Rett syndrome community to join us in sending heartfelt thoughts to her family, friends and the dedicated clinicians who are caring for her," said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. "The safety of the participants in our clinical trial is and remains our foremost priority as we work to find solutions for this devastating disease."
In a commitment to full transparency with the U.S. Food and Drug Administration (FDA), Neurogene proactively engaged with the FDA under the START program following the Company's notification of the SAE. The FDA completed a review of the safety data for NGN-401 and allowed Neurogene to proceed with the Phase 1/2 trial using the 1E15 vg dose (low-dose cohort). Neurogene paused further use of the 3E15 vg dose (high-dose cohorts) upon initial notification of the SAE and does not plan to enroll any further participants at the 3E15 vg dose level.
To date, there have been no other treatment-related SAEs in the clinical trial, including in the five participants who received the 1E15 vg dose (low-dose cohort) and in the first two participants who received the 3E15 vg dose (high-dose cohort) of NGN-401. All treatment-related AEs in the 1E15 vg cohort (low-dose cohort) have been Grade 1 (mild). Most treatment-related AEs are known potential risks of AAV, have been responsive to steroids, and have resolved or are resolving. There have been no signs or symptoms indicative of MeCP2 overexpression toxicity. In addition, there have been no intracerebroventricular (ICV) procedure-related AEs.
Neurogene no longer anticipates completing enrollment in the 1E15 vg cohort (low-dose cohort) of NGN-401 in the fourth quarter of 2024 as the Company updates the protocol to reflect the discontinuation of the 3E15 vg dose.

NGNE

Neurogene Halts High-Dose Gene Therapy Trial After Serious Adverse Event in Rett Syndrome Patient

To support this transition, following Gori's retirement he has agreed to serve as an Advisor through August 31, 2025.

Manulife Financial President And CEO Roy Gori Intends To Retire, Effective May 8, 2025, With Phil Witherington Appointed As His Successor

<ul>
<li>We are revising our annual revenue guidance for 2024 increasing the lower range of our revenue guidance from $540 million to $544 million reflecting our continued solid momentum for the remaining part of the year and positive outlook. Our full year revenues guidance for 2024 is $544 million to $550 million.</li>
</ul>

Guidance

MGIC

Magic Software Enterprises Expects FY24 Revenue Of $544M-$550M (Prior $540M-$550M) Vs $544.87M Est

Earnings

Earnings Beats

Earnings Misses

Magic Software Q3 2024 Adj. EPS $0.23 Misses $0.25 Estimate, Sales $142.968M Beat $137.776M Estimate

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) plans to issue U.S. dollars and Chinese yuan bonds to raise capital. The company aims to repay existing debt and support an ongoing stock buyback initiative.
The decision to tap the bond market comes as the company seeks to leverage low global interest rates, providing an opportunity to replenish its capital base while enhancing shareholder value.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/11/41984426/nvidia-powers-teslas-humanoid-robots-with-new-ai-tech-heres-what-to-expect-in-2025" rel="noreferrer noopener">Nvidia Powers Tesla&#8217;s Humanoid Robots With New AI Tech: Here&#8217;s What To Expect In 2025</a>
The exact principal amount, interest rates, and maturity terms for the bonds will be determined at the time of pricing, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3287038/alibaba-sell-bonds-repay-debt-fund-stock-buy-back-amid-low-interest-rates" rel="noreferrer noopener">cites</a> a filing with the Hong Kong Stock Exchange.
The issuance will likely generate up to $5 billion, with Reuters indicating the dollar-denominated bonds will have maturities of 5.5, 10.5, and 30 years.
The yuan-denominated bonds will carry tenors of 3.5, 5, 10, and 20 years, showcasing a broad range of options for potential investors.
Market analysts suggest that declining interest rates in the Asia-Pacific region have made debt issuance an attractive option for companies like Alibaba. This enables them to execute share buybacks and invest strategically without incurring high financing costs.
Kenny Ng Lai-yin, a strategist at Everbright Securities International, told the SCMP that this environment offers a unique chance for firms to enhance capital returns through debt financing.
Last week, Alibaba reported <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42006281/alibaba-q2-earnings-revenue-beats-forecast-cloud-and-international-sales-shine-free-cash-flow-falls-amid-strategic-investments" rel="noreferrer noopener">fiscal second-quarter 2024</a> revenue growth of 5% to $33.70 billion, beating the analyst consensus of $33.47 billion.
Taobao and Tmall Group revenue grew by 1% to $14.11 billion,
Alibaba International Digital Commerce Group&#8217;s revenue increased by 29% to $4.51 billion, and Local Services Group revenue grew by 14% to $2.53 billion.&nbsp;
Cainiao Smart Logistics Network Limited&#8217;s revenue increased 8% to $3.51 billion.&nbsp; Cloud Intelligence Group revenue grew by 7% to $4.22 billion.&nbsp;
As of September 30, Alibaba reported total outstanding liabilities of 202.2 billion yuan ($27.9 billion) in bank loans and bonds, marking an 18% increase since March.
The company raised $5.5 billion in May through a convertible bond issue. The current bond offering aligns with Alibaba&#8217;s aggressive stock repurchase program, initiated during the pandemic in 2020.
Yields on U.S. Treasuries are currently around 4.31% for five-year notes, 4.44% for ten-year notes, and 3.62% for thirty-year bonds. In contrast, Chinese government bonds offer significantly lower yields, with three-year and five-year bonds yielding 1.35% and 1.7%, respectively.
This disparity provides Alibaba with favorable conditions for its planned bond issuance, reducing the overall cost of borrowing.
The company&#8217;s strategic push to increase buybacks reflects a broader trend among top Chinese tech firms, driven by steep declines in stock valuations.
Alibaba&#8217;s shares have fallen approximately 70% from their peak in late 2020 despite continued growth in sales and profits due to economic weakness, domestic regulatory crackdown, and <a target="_blank" href="https://www.benzinga.com/24/11/41911946/whats-going-on-with-us-listed-chinese-stocks-like-alibaba-jd-nio-on-tuesday" rel="noreferrer noopener">disappointing fiscal stimulus</a>.
During the third quarter, Alibaba repurchased $4.1 billion worth of shares, reducing its outstanding share count by 2.1% from the end of June. The company&#8217;s CFO, Toby Xu Hong, emphasized the importance of these buybacks as a signal of confidence in Alibaba&#8217;s business outlook.
Michael Burry&#8217;s fund <a target="_blank" href="https://www.benzinga.com/news/global/24/11/42002224/big-short-investor-michael-burry-doubles-down-on-chinese-tech-stocks-while-adding-protective-hedges" rel="noreferrer noopener">increased its stakes in</a> Alibaba, JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), making Chinese tech its largest holdings.
Despite boosting exposure, Burry hedged risks by purchasing put options, signaling caution on potential market volatility.
Price Action:&nbsp;BABA stock is up 0.42% at $88.96 premarket at&nbsp;the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41981957/meta-hit-with-841-million-eu-fine-over-antitrust-violations-tied-to-facebook-marketplace" target="_blank" rel="noreferrer noopener">Meta Hit With $841 Million EU Fine Over Antitrust Violations Tied To Facebook Marketplace</a></li>
</ul>
Image via Shutterstock

Emerging Markets

Buybacks

Tech

Media

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Alibaba Eyes Raising $5 Billion Via Bond Sale to Fund Debt Payoff and Stock Buybacks

Perpetua Resources Corp. (Nasdaq:&nbsp;PPTA) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#TSX">PPTA</a>)&nbsp;("Perpetua Resources" or the "Company") today announced the launch of a public offering of 3,439,465 shares of its common stock (the "Common Shares") in the United States ( the "Offering").
The Company expects to use the net proceeds of the Offering for down payments on long lead time materials, detailed engineering for its Stibnite Gold Project, and general corporate purposes.
The Common Shares will be offered by the Company with BMO Capital Markets and National Bank of Canada Financial Markets acting as joint lead book-running managers and RBC Capital Markets and Cantor acting as joint book-running managers (collectively, the "Underwriters").&nbsp;
Perpetua Resources intends to grant the Underwriters an option, exercisable for a period of 30 days from the date hereof, to purchase up to an additional 515,919 Common Shares representing up to 15% of the number of Common Shares to be sold pursuant to the Offering.

PPTA

TSX:PPTA

Perpetua Resources Launches Public Offering Of 3.44 Million Shares to Fund Stibnite Gold Project Expansion

Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) shares are trading higher premarket on Monday. The company disclosed a restructuring support agreement (RSA) with a supermajority of its loyalty and convertible bondholders to implement a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42030743/spirit-airlines-announces-comprehensive-agreement-to-deleverage-balance-sheet-and-position-the-com" rel="noreferrer noopener">comprehensive balance sheet restructuring</a>.
The plan aims to reduce debt, enhance financial flexibility, support long-term success, and accelerate investments to improve guest travel experiences and value.
The company&#8217;s key measures include a $350 million backstopped equity investment from existing bondholders and the equitization of $795 million in funded debt.
Additionally, bondholders are providing $300 million in DIP financing, complemented by Spirit&#8217;s cash reserves and operational cash flow, to support the restructuring process.
Spirit has filed a Plan of Reorganization as part of its Chapter 11 process, incorporating the terms of the RSA and awaiting Court approval.
With support from a supermajority of loyalty and convertible bondholders, the company expects to emerge from Chapter 11 in the&nbsp;first quarter of 2025.
First-day motions are also being filed to ensure normal business operations during the process.
As a result of the filing, Spirit anticipates being delisted from the NYSE soon, with its common stock continuing to trade over-the-counter. The shares are expected to be canceled and hold no value as part of the restructuring.
Ted Christie, Spirit&#8217;s President and Chief Executive Officer, said, &#8220;This set of transactions will materially strengthen our balance sheet and position Spirit for the future while we continue executing on our strategic initiatives to transform our Guest experience, providing new enhanced travel options, greater value and increased flexibility.&#8221;&nbsp;
Last week, Spirit filed the form, signaling it cannot submit its 2024 third-quarter earnings on time, as the company has diverted resources from reviewing and completing financial statements to<a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/41946520/whats-going-on-with-spirit-airlines-stock-wednesday-2" rel="noreferrer noopener"> ongoing debt restructuring discussions</a>.
This came after Spirit&#8217;s merger conversations with Fronter Group Holdings Inc. and and its takeover by&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41932146/spirit-airlines-nears-bankruptcy-creditors-may-approve-equity-cancellation-heres-what-it-means-for-investors-as-shares-fall-with-a-thud" rel="noreferrer noopener">JetBlue Airways</a><a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41932146/spirit-airlines-nears-bankruptcy-creditors-may-approve-equity-cancellation-heres-what-it-means-for-investors-as-shares-fall-with-a-thud" rel="noreferrer noopener"> fell through</a>.
Price Action: SAVE shares are up 3.70% at $1.12 premarket at the last check Monday.
Photo: Courtesy of Smart Calendar via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/ma/24/11/42025534/deal-dispatch-shell-unilever-and-more-are-on-the-sell-side-the-onion-makes-alex-jones-cry-foul" target="_blank" rel="noreferrer noopener">Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul</a></li>
</ul>

Equities

Small Cap

Movers

SAVE

Spirit Airlines Eyes Restructuring With Chapter 11 Filing And Equity Injection

DThe Board of Directors of CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) today announced the appointment of four new board members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management.
"In our discussions with the leadership at Glenview, we agreed that we can deliver greater value from our integrated businesses to all of our stakeholders, including our customers, consumers, colleagues, and shareholders," said Roger Farah, Executive Chairman of the Board, CVS Health. "Having Leslie, Larry, Guy, and Doug join our Board will add new thinking and deep market and industry experiences as we focus on driving greater financial and operational performance."
"As we build momentum across our integrated model, we continue to take actions that are positive for our long-term success, while driving innovation and performance in our individual businesses and at CVS Health overall," said David Joyner, president and chief executive officer of CVS Health. "Adding four experienced thought leaders to our Board further sharpens our focus on executing against our strategy to build a world of health around every consumer, as we improve total cost of care and customer experience in health care."
"We welcome the opportunity to join the Board, roll up our sleeves and lock arms with the Board and leadership team to drive long-term, sustainable value through continued customer-centric offerings, commitment to compliance and quality, disciplined underwriting and risk management, aligned incentives, and optimal capital allocation," said Larry Robbins, CEO of Glenview Capital Management.&nbsp; "We appreciate the Board engaging with us on a cooperative basis that allows all energies to be productively dedicated towards further strengthening this iconic company."
Norwalk will join the Health Services Committee, Sansone will join the Audit Committee, and Shulman will join the Management Planning and Development Committee.

CVS Health Adds Four New Directors Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman After Discussing With Glenview Capital Management, Strengthening Board With Industry Veterans

"The Board of Directors' approval of this stock repurchase program reflects confidence in the Company's balance sheet and business outlook," said Rajiv K. Prasad, President and Chief Executive Officer of Hyster-Yale, Inc. "This stock repurchase authorization is well aligned with our capital allocation strategy designed to support long-term profitable growth and fuel shareholder return as the business generates free cash flow."

Hyster-Yale Approves $50M Buyback Plan, Aims To Repurchase Up To 1.5M Shares

TD Cowen analyst Marc Frahm has maintained their bullish stance on KYMR stock, giving a Buy rating on October 24. Marc Frahm has given his Buy rati...

Kymera Therapeutics: Strategic Focus and Promising Trials Justify Buy Rating

Kymera Therapeutics, Inc. ( ($KYMR) ) has released its Q3 earnings. Here is a breakdown of the information Kymera Therapeutics, Inc. presented to i...

Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price ...

Kymera Therapeutics: Promising Immunology Pipeline and Strategic Focus on KT-621 and KT-474 Programs

U.S. drugmakers and biotechs rely on Chinese partners for manufacturing, research, and ingredients, but, with geopolitical tensions rising, compani...

U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a pri...

Stifel Nicolaus Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price targe...

Oppenheimer Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Guggenheim raised the firm's price target on Kymera Therapeutics (KYMR) to $52 from $45 and keeps a Buy rating on the shares. The firm is updating ...

Kymera Therapeutics price target raised to $52 from $45 at Guggenheim

Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript

Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV – Research Report), Halozyme (HALO – Research...

Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report),...

Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)

ALNY

AZNCF

FOLD

HALO

IVVD

KYMR

Financing

Press Releases

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

Health Care

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

General

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

Comments

Kymera Therapeutics

Actualités

Dernières nouvelles pour Kymera Therapeutics (NASDAQ:KYMR) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL